Here's How IDEXX Laboratories is Placed Ahead of Q3 Earnings

Core Insights - IDEXX Laboratories, Inc. (IDXX) is scheduled to release its third-quarter 2025 results on November 3, before the market opens, with expectations of strong performance based on previous quarters [1][9] Revenue and Earnings Estimates - The Zacks Consensus Estimate for revenues is $1.07 billion, reflecting a 9.8% increase from the previous year [2][9] - The Zacks Consensus Estimate for EPS is $3.14, indicating a rise of 12.1% year-over-year [2][9] Performance Drivers - The Companion Animal Group (CAG) is anticipated to significantly contribute to IDEXX's revenue, driven by strong global execution, higher price realization, and increased test volumes [4][9] - The adoption of innovations like the Catalyst Pancreatic Lipase and the IDEXX Cancer Dx diagnostic panel is expected to enhance revenue from CAG Diagnostics [5][9] - Robust placements of premium instruments, particularly the IDEXX inVue Dx Analyzer, are likely to support growth in diagnostic services and accessories [6][9] Segment Performance - CAG business revenues are projected to increase by 10% year-over-year in Q3 2025 [7] - The Water segment is expected to benefit from higher testing volumes in Europe and Asia Pacific, with an estimated 8.6% year-over-year growth [10] - The Livestock, Poultry, and Dairy (LPD) division is forecasted to see a 5% year-over-year increase in revenues, supported by high test volumes and favorable price realization [11] Earnings Expectations - IDEXX Laboratories has an Earnings ESP of +0.23%, indicating a higher likelihood of beating estimates [12] - The company currently holds a Zacks Rank of 2 (Buy), suggesting positive market sentiment [13]